In light of Anavex’s announcement of its first entire clinical gene pathway data in patients with Rett syndrome, coupled with Mission Therapeutics’ recent fundraising of £25.2 million to progress the clinical development of its lead drug candidates, there has been increasing evidence of interest taking place towards broader disease groups with underlying pathogenesis from mitochondrial dysfunction.

This November, we will unite 60+ C-Level, Biologist, Preclinical, Translational, and Innovation-Scouting Leaders who are building on from the industry’s latest setbacks to innovate mitochondrial-targeting approaches and expand novel therapeutic opportunities. From cutting-edge research backed by academia to transformative pipeline updates from preclinical and clinical settings revealed by the industry, this is your chance to get involved and de-risk clinical development by discovering and validating biomarkers for defined endpoints.